Aequus Pharmaceuticals IncOTCQB:AQSZFView on Canadian Exchange
- LAST PRICE0.0177
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0112/ 113
- Ask / Lots0.0183/ 113
- Open / Previous Close0.0000 / 0.0177
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
May 9, 2024
Aequus Provides General Update and First Quarter 2024 Financial Highlights, Grant Stock Options and Financing, from 7:05PM ET on Thursday May 09, 2024 by Dow Jones
7:05PM ET on Thursday May 09, 2024 by Dow Jones
May 7, 2024
Aequus Poised to Fill Bimatoprost 0.03% Drug Shortage in Canada, from 4:10PM ET on Tuesday May 07, 2024 by Dow Jones
4:10PM ET on Tuesday May 07, 2024 by Dow Jones
Apr 29, 2024
Aequus Provides General Update and Fiscal 2023 Financial Results, from 10:30PM ET on Monday Apr 29, 2024 by Dow Jones
10:30PM ET on Monday Apr 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aequus Pharmaceuticals Inc | 2.7M | 0.0x | --- |
Company Information
Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company focused on developing, advancing, and promoting differentiated products. The Company is engaged in the sale and marketing of several commercial products in ophthalmology and transplant. Its pipeline products include Evolve Intensive Gel, Evolve Daily Intensive, SCOPE Portfolio, Zimed PF and REV-0100 / ReVision. Evolve Intensive Gel and Evolve Daily Intensive contains lubricating eye drops intended for use in the relief of discomfort that arises from dry eye sensations, including dryness, soreness, feelings of grit, and irritation. Zimed PF is a preservative-free multi-dose Bimatoprost for glaucoma patients in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. It plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license.
Contact Information
- Headquarters
- 595 Burrard Street, Suite 2600VANCOUVER, BC, Canada V7X 1L3
- Phone
- 604-336-7906
- Fax
- 604-336-7906
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7M |
|---|---|
Revenue (TTM) | $215.2K |
Shares Outstanding | 132.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.20 |
EPS | $-0.02 |
Book Value | $-0.03 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 12.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,340.06% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
